Review
Multigene tests in assessing and treating early endocrine-dependent breast cancer
Shuting Zuo, Jianfen Hua, Liping Zhao, Yan Zhang
Published 2018-10-25
Cite as Chin J Endocr Surg, 2018, 12(5): 422-425. DOI: 10.3760/cma.j.issn.1674-6090.2018.05.016
Abstract
Detection of Oncotype DX and MammaPrint has been recommended by the American Society of Clinical Oncology. For specific populations, such as early endocrine-dependent breast cancer, under the condition of sufficient evidence in the evidence-based medicine, we can choose genetic testing in combination with clinical pathologic factors to guide clinical treatment, which has reached the goal of micro combined with macro, more detailed division of the patients, and individualized treatment.
Key words:
Multigene test; Oncotype DX; MammaPrint; Breast cancer; Distant recurrence
Contributor Information
Shuting Zuo
Department of Breast Surgery, Second Hospital of Jilin University, Changchun 130041, China
Jianfen Hua
Department of Breast Surgery, Second Hospital of Jilin University, Changchun 130041, China
Liping Zhao
Department of Obstetrics and Gynecology, Second Hospital of Jilin University, Changchun 130041, China
Yan Zhang
Department of Breast Surgery, Second Hospital of Jilin University, Changchun 130041, China